BioVenture, established in September 2013, specializes in early-stage venture capital investments in the field of life sciences, focusing on biotechnology, drug discovery, medical devices, and healthcare services companies. With a fund size of 540 million yuan, BioVenture provides capital and post-investment support to innovative companies with high growth potential. Backed by Suzhou Industrial Park and BioBay, BioVenture aims to become one of China's most successful medical and pharmaceutical venture funds by leveraging its industry expertise and resources. The team at BioVenture consists of senior investment professionals with deep knowledge of domestic and foreign markets, aiming to help companies grow rapidly and achieve greater success while delivering considerable returns to fund investors. Through joint venture development cooperation, BioVenture seeks to drive innovation and growth in the medical and pharmaceutical industry.
Hengyu Medical is a medical device firm focused on R&D and production of IVUS and optical coherence tomography, and catheter equipment.
AusperBio
Series B in 2024
AusperBio is a clinical-stage biopharmaceutical company focused on developing innovative treatments for hepatitis B and advancing oligonucleotide therapeutics. Utilizing its proprietary Med-Oligo™ ASO platform, the company aims to enhance targeted delivery technologies to improve treatment outcomes. AusperBio is dedicated to addressing a variety of diseases, including viral infections, genetic disorders, metabolic conditions, and immune diseases, through its small interfering ribonucleic acid (siRNA) drugs. By concentrating on effective treatment strategies and vaccination for chronic hepatitis B, AusperBio seeks to provide patients with improved therapeutic options and protection against this challenging disease.
Shenzhen CardioACC
Seed Round in 2023
Shenzhen CardioACC Ltd specializes in advanced cardiovascular interventional, natural cavity imaging and advanced diagnostic procedures.
Huili Pharmaceutical
Series A in 2023
Huili Pharmaceutical is a drug delivery platform that specializes in the development of nanoparticles and microsphere preparation equipment.
Shennapsi Artificial Intelligence Technology
Series A in 2023
Synapsor is a medical-grade wearable device research and development company, oriented to the AI+ medical and health field, and is committed to the development and manufacturing of AI-powered medical-grade smart wearable devices, including AI-ECG artificial intelligence. Diagnostic analysis system, CUMS uric acid blood glucose and cholesterol monitoring system, etc. The company has recently received tens of millions of yuan in Series B investment, and the investor is Xiaomi Technology.
Essentia Biosciences
Angel Round in 2023
Essentia Biosciences is a biotechnology company that specializes in the development of cells, gene technology drugs, and medical devices.
Power Site
Series B in 2023
Power Site is a modern technology enterprise that supplies X-ray imaging core components. It mainly provides high-voltage generators (HVG), combined X-ray sources, power distribution units (PDU), and other core components overall solutions for X-ray imaging systems. The products are mainly used in high-end X-ray imaging systems such as CT, DR, mammography, C-arm, CBCT, security inspection, industrial inspection, etc. The company has an advanced and efficient manufacturing platform with an annual production capacity of 50,000 units.
Yike Polymers
Series B in 2023
Eco Polymer specializes in designing and manufacturing plastic tubes and parts. They provide products for polyethylene, polypropylene, polyamine, elastomers, fluoropolymers, and other various polymers. They serve the medical instrument, auto, electronics, fiber optics, semiconductor, chemical engineering, environment, and analytics industries.
Hanchao Pharmaceutical
Venture Round in 2023
Hanchao Pharmaceutical is a biopharmaceutical company that specializes in the development and production of medical equipment and solutions for the biomedical industry. The company's core focus is on providing single-use bioprocessing solutions, with a particular emphasis on biomedical production technology. Hanchao independently designs, manufactures, and sells a range of equipment and consumables, catering to the industrialization stage of various biomedical fields, including antibodies, vaccines, antibody-drug conjugates (ADCs), and cell and gene therapies (CGTs).
Pulnovo Medical
Venture Round in 2022
Pulnovo Medical, founded in 2013 in Wuxi, Anhui, specializes in the development, production, and service of innovative medical devices aimed at treating pulmonary hypertension. The company focuses on advanced pulse radiofrequency ablation technology, which includes pioneering high-frequency ablation equipment and intravascular catheters. These products are designed to enhance the quality of life for patients suffering from pulmonary hypertension and heart failure, offering a novel approach to treatment with a commitment to improving patient outcomes. Pulnovo Medical holds global invention patents for its unique technologies, underscoring its role as a leader in this specialized medical field.
Zhongguancun Shuimu Medical Technology
Series A in 2022
Zhongguancun Shuimu Medical Technology is the operator of a third-party, competent medical device compliance organization. Their business helps companies cut costs and time to market by offering medical device compliance services. It is dedicated to accelerating the registration and listing procedures for new medical device items as well as addressing the issue of how to industrialize creative medical device firms.
Joymed Technology
Series B in 2022
Joymed Technology specializes in the research and development, registration, and manufacturing of medical devices, providing comprehensive solutions tailored for medical equipment businesses. The company focuses on delivering innovative and reliable technology while ensuring high-quality standards in its products. By offering services such as device design, risk management, marketing, and product verification and validation, Joymed Technology enables its clients to develop and launch safe and affordable medical products efficiently. The company aims to become a trusted partner for both domestic and international medical device firms, particularly assisting small and medium-sized enterprises in navigating the complexities of the medical product market. Through flexible collaboration and optimized design processes, Joymed Technology seeks to accelerate mutual growth with its customers.
AccuPulse
Series A in 2022
AccuPulse is focused on the development of a pulsed electric field ablation (PFA) system designed to treat atrial fibrillation (A-fib). The company offers a comprehensive solution that includes both a PFA generator and specialized catheters for the pulse ablation of A-fib and tumors. By integrating advanced technologies, AccuPulse aims to enhance catheter localization and signal acquisition, while also improving the overall efficiency of interventional therapies that utilize radio frequency and cryotherapy. This innovative approach seeks to provide healthcare professionals and patients with a more effective and intelligent treatment option for managing A-fib and related conditions.
KingstronBio
Series C in 2021
KingstronBio specializes in the development and manufacturing of advanced heart valve products for cardiac surgeries. The company offers a comprehensive range of biological heart valves, focusing on minimally invasive solutions that enhance patient outcomes. Utilizing cutting-edge technologies, including anti-calcification, dry presentation, and leaflet thinning, KingstronBio aims to deliver innovative and effective products to the medical community, thereby addressing critical needs in cardiovascular care.
Tripod Preclinical Research
Venture Round in 2021
Tripod Preclinical Research is a Contract Research Organization that specializes in providing preclinical research services to the biopharmaceutical and medical device industries. The company offers a comprehensive range of services, including drug safety evaluation for new chemical entities, food additives, biologics, pesticides, veterinary drugs, and cosmetics. Tripod's expertise encompasses non-human primate disease models, pharmacological efficacy studies, early drug evaluation, and Good Laboratory Practices (GLP) toxicology. Additionally, the organization supports translational medicine and clinical trials, along with biological analysis and the management of biological sample banks. By delivering these services, Tripod aids drug developers and researchers in advancing their projects through the critical early stages of research and development.
Guangzhou Creative Biosciences
Series D in 2021
Guangzhou Creative Biosciences, established in Guangzhou, China, is a biomedical technology company specializing in the research, development, production, and sales of diagnostic kits for early cancer detection. Its primary focus is on colorectal cancer, offering non-invasive fecal screening kits that detect genetic abnormalities in feces, aiding practitioners in identifying early intestinal cancer lesions. Additionally, the company develops and sells diagnostic kits and equipment for lung cancer.
Vision X
Series B in 2021
Vision X is a solutions provider for medical equipment in the field of ophthalmology and optometry.
IntoCare
Series D in 2021
IntoCare is a high-tech company specializing in surgical products such as "Smart" powered staplers.
Brattea
Series B in 2021
Brattea is a medical device research and development company specializing in renal denervation products aimed at treating conditions such as hypertension, cancer pain, and diabetes. The company develops interventional devices, including renal artery ablation catheters and radiofrequency ablation equipment, as well as medical mapping systems. These products are designed to address a range of health issues, including refractory hypertension, obstructive sleep apnea, kidney disease, and heart failure. Brattea is committed to providing reliable medical solutions that enhance patient care and improve health outcomes.
Synaptic Medical
Series G in 2021
Synaptic Medical Inc. is a medical device company that develops and commercializes products aimed at treating cardiac arrhythmias and other cardiovascular diseases. Founded in 2005, the company operates from its headquarters in St. Paul, Minnesota, and has an additional office in Beijing, China. Synaptic Medical specializes in cardiac electrophysiology products, including bipolar pacing systems, fixed curve and deflectable diagnostic catheters, pulmonary vein mapping catheters, and ablation technologies. The company's mission is to create innovative, cost-effective, and clinically advanced solutions that enhance treatment options for physicians and their patients.
HuiKai
Series A in 2021
HuiKai Medical focuses on the research and development, as well as the manufacturing of medical devices tailored for the urinary system. The company's product range addresses various urological conditions, including prostatic hyperplasia, urinary stones, urinary incontinence, and urological tumors. By employing proprietary technology and innovative materials, HuiKai Medical aims to enhance patient comfort and streamline procedures, thereby improving overall healthcare efficiency and outcomes.
Yingsheng Biology
Series B in 2020
Yingsheng Biotechnology Co., Ltd., established in 2009, specializes in the development and production of in vitro diagnostic reagents and medical equipment focused on maternal and child health, neonatal genetic diseases, and metabolic disorders. The company offers a diverse range of products, including 45 innovative genetic metabolic disease screening reagents, deaf genetic testing kits, and HLA-B27 detection kits. These products aim to facilitate early detection of genetic conditions and birth defects, promoting timely intervention and disease prevention. Yingsheng Bio utilizes advanced molecular diagnostic techniques and sophisticated detection systems, contributing significantly to the fields of human genetics and public health.
Genskey
Series C in 2020
GensKey is a medical diagnostic service provider specializing in genetic testing for pathogen diagnosis. Utilizing high-throughput sequencing technology and intelligent algorithm analysis, GensKey addresses traditional challenges such as low detection rates, lengthy processes, and diagnostic accuracy. This innovative approach allows for timely and precise diagnoses for patients suffering from severe infections, ultimately improving patient outcomes by facilitating quicker access to appropriate medical interventions.
Zylox Medical Device
Series C in 2020
Zylox Medical Device Co., founded in 2012 in Hangzhou, is a specialized company focused on developing innovative medical devices for interventional procedures. Established by a team of experienced professionals with backgrounds in top-tier medical device manufacturers, Zylox offers a diverse range of products primarily aimed at peripheral vascular and neurovascular interventions. Its product line includes various devices such as PTA balloons, drug-coated PTA balloons, superficial femoral artery (SFA) stents, and the Thrombite Clot Retriever Device. Zylox is committed to improving patient outcomes by consistently enhancing its cutting-edge medical technologies and ensuring the highest quality standards.
Delta Medical
Series D in 2020
Beijing Delta Medical Co., Ltd. specializes in the design and manufacture of orthopedic surgical instruments and rehabilitation products. The company offers a range of products, including shoulder arthroscopic instruments, various types of suture anchors, instruments for anterior and posterior cruciate ligament reconstruction, interference screws, and shaver systems. In addition to its surgical instruments, Delta Medical provides sports rehabilitation services. The company is headquartered in Beijing, China, and focuses on delivering innovative solutions in sports medicine.
IntoCare
Series C in 2020
IntoCare is a high-tech company specializing in surgical products such as "Smart" powered staplers.
Ruixun Biotech
Series A in 2019
Ruixun Biotech is a healthcare company that provides biotechnology. Ruixun Biotech combines microfluidics, optics, precision instruments, electronic engineering, and biochemical technologies to create upstream equipment and consumables for molecular diagnosis and genetic testing. They released a number of products, including the digital PCR apparatus DropX-2000 and more than 50 different RUO detection kits.
DiaMonTech
Series A in 2019
DiaMonTech AG is a medical technology company based in Berlin, Germany, focused on developing non-invasive diagnostic devices for blood glucose monitoring. Founded in 2015, the company utilizes a proprietary laser-based photo-thermal detection technology to measure glucose levels without the need for blood draws or finger pricking, thereby offering a painless alternative for diabetes management. DiaMonTech's product lineup includes the D-BASE, a device designed for human trials, the D-pocket, a compact personal device for frequent glucose tracking, and the D-BAND, a wearable device that continuously monitors blood sugar levels. Through its innovative solutions, DiaMonTech aims to enhance the quality of life for individuals managing diabetes.
Antekang Cheng
Seed Round in 2019
Antai Kangcheng is a research and development company specializing in tumor electric field treatment technology, primarily aimed at addressing glioblastoma multiforme. The firm focuses on creating innovative treatment methods for tumors, as well as technologies for central nervous system injury repair and neurorehabilitation. Antai Kangcheng has developed a precise treatment planning system that utilizes biophysical models and multimodal imaging systems, enabling the visualization of intracranial field strength. This capability allows for effective management of electro-nodes to track tumors within the electric field, facilitating personalized treatment approaches for cancer patients, particularly in the Chinese market. The company's commitment to improving treatment affordability and effectiveness underscores its dedication to advancing cancer care.
Just Medical
Series A in 2019
Just Medical is a developer and manufacturer of orthopedic medical devices, specializing in artificial implants such as hip and knee joints, as well as internal fixation products and surgical instruments. The company emphasizes research and development in orthopedics, aiming to enhance surgical efficiency and improve the quality of orthopedic treatment. Just Medical is dedicated to providing safe and effective medical products and services, continually refining its product systems to alleviate patient pain and support healthcare professionals in their surgical procedures.
Joinspine
Series A in 2019
Joinspine is one of the few Chinese companies that have some core patients in the field of spinal surgery and spine endoscopy industry. The current team is using the latest new technologies to improve its auxiliary robot and AI. Based on advanced foreign technologies and their own Development, Jlecheng Medical believes they can help this industry to improve in China.
Yingsheng Biology
Series C in 2019
Yingsheng Biotechnology Co., Ltd., established in 2009, specializes in the development and production of in vitro diagnostic reagents and medical equipment focused on maternal and child health, neonatal genetic diseases, and metabolic disorders. The company offers a diverse range of products, including 45 innovative genetic metabolic disease screening reagents, deaf genetic testing kits, and HLA-B27 detection kits. These products aim to facilitate early detection of genetic conditions and birth defects, promoting timely intervention and disease prevention. Yingsheng Bio utilizes advanced molecular diagnostic techniques and sophisticated detection systems, contributing significantly to the fields of human genetics and public health.
CART Medical
Series A in 2019
CART Medical Technologies, Ltd. is a high-tech company focused on advancing immune cell therapy through innovative technologies. With a substantial GMP laboratory and research and development facility spanning 2,200 square meters, the company is at the forefront of developing CAR-T cell treatments. CART Medical's approach involves utilizing both protein antigens and glycolipid non-protein antigens to broaden the spectrum of tumor antigen targets. This strategy enhances T-cell generation and activation via a novel CAR-T structural gene sequence, ultimately providing patients with more effective treatment options for various diseases and illnesses.
Isia Biotech
Venture Round in 2019
Isia Biotech specializes in the research, development, production, and sales of in vitro diagnostic (IVD) medical technology. The company focuses on leveraging proprietary quantum dot technology to enhance diagnostic accuracy through immune reactions. Its innovative products are designed to detect and diagnose various health conditions, including cardiovascular diseases, inflammation, bone metabolism issues, gastric and renal functions, cancer, and autoimmune diseases. By improving the ability of healthcare professionals to detect and diagnose these diseases, Isia Biotech aims to contribute significantly to patient care and treatment outcomes.
DeepCyto
Venture Round in 2019
DeepCyto is a medtech company established in 2018 and headquartered in Suzhou, Jiangsu, China. The company specializes in the development of digital hematology pathology and diagnostic equipment, integrating artificial intelligence and deep learning technologies into medical diagnosis and data analysis. By leveraging machine vision and big data mining, DeepCyto offers intelligent diagnostic models for a range of blood diseases, enhancing the accuracy and efficiency of medical assessments.
Novaprint Therapeutics
Venture Round in 2019
Novaprint Therapeutics develops and supplies regenerative medical implant devices. The company utilizes 3D printing technology to design and develop regenerative medical implant devices, enabling patients to receive more customized and effective medical treatment.
AGS MedTech
Series A in 2018
AGS MedTech specializes in the design, development, and production of endoscopic, minimally invasive devices for interventional diagnosis and treatment. The company focuses on research and development to create innovative solutions that enhance patient care while reducing pain and medical costs. By prioritizing safety and efficiency, AGS MedTech aims to provide both patients and clinicians with advanced tools that facilitate effective medical procedures.
Innovita Biological Technology
Series B in 2018
Established in 2006 in Beijing, Innovita Biological Technology Co., Ltd. is a Chinese high-tech enterprise specialized in R&D, manufacturing, marketing and after-sales service of In-vitro diagnostic tests. In 2011 Innovita extended a new plant in Tangshan city of Hebei province-Innovita (Tangshan) Biological Technology Co., Ltd., which was designed as five new production lines: colloidal gold, real-time PCR, chemiluminescence, ELISA and biochips. The facility covers 250 acres (160,000 square meters) and is equipped with a purification plant of 4,000 square meters. The designed annual output can reach 20 million tests. Currently they have got ten invention patents. With certification of CE, ISO 13485 and GMP, Innovita has an extensive product line covering Fertility, Infectious Diseases, Sexually Transmitted Diseases, TORCH, Respiratory Diseases, Drug Abuse, Tumor Marker and Cardiac marker tests.
Delta Medical
Series B in 2018
Beijing Delta Medical Co., Ltd. specializes in the design and manufacture of orthopedic surgical instruments and rehabilitation products. The company offers a range of products, including shoulder arthroscopic instruments, various types of suture anchors, instruments for anterior and posterior cruciate ligament reconstruction, interference screws, and shaver systems. In addition to its surgical instruments, Delta Medical provides sports rehabilitation services. The company is headquartered in Beijing, China, and focuses on delivering innovative solutions in sports medicine.
Senscure Biotechnology
Series A in 2018
Ningbo Senscure Biotechnology Co., Ltd specializes in the innovation and enhancement of minimally invasive surgery technologies, particularly focusing on single incision laparoscopic surgery (SILS) and natural orifice transluminal endoscopic surgery (NOTES). The company emphasizes tumor treatment and offers a comprehensive range of surgical devices, including a laparoscopic single port multi-channel access platform, a pulmonary nodule localization needle, a tumor cryoablation system, and an anti-gastroesophageal reflux system. These products aim to provide complete medical equipment solutions for minimally invasive surgical procedures.
Cryofocus Biotech
Series A in 2018
Cryofocus Biotech is a Shanghai-based cryoablation device manufacturer, focusing on the application of cryogenic technology in the field of cardiovascular interventional therapy.
Claricare Medical
Venture Round in 2018
Claricare Medical is an innovative developer of oncology vascular interventional therapeutic services.
LenoMed Medical
Series A in 2017
LenoMed Medical is a manufacturer of medical devices focused on improving diabetes management. With over 15 years of research and development experience in infusion technology, the company specializes in creating innovative products such as the InnoTech insulin pump, drug infusion pumps, and related disposables. LenoMed is dedicated to enhancing diabetes care through the integration of continuous glucose monitoring technology with their insulin pumps, aiming to provide patients with better treatment options and monitoring capabilities. Their commitment to advancing diabetes management is reflected in their comprehensive diabetes care management system.
KingstronBio
Series A in 2016
KingstronBio specializes in the development and manufacturing of advanced heart valve products for cardiac surgeries. The company offers a comprehensive range of biological heart valves, focusing on minimally invasive solutions that enhance patient outcomes. Utilizing cutting-edge technologies, including anti-calcification, dry presentation, and leaflet thinning, KingstronBio aims to deliver innovative and effective products to the medical community, thereby addressing critical needs in cardiovascular care.
Aixing Biotechnology
Venture Round in 2016
Aixing Biotechnology manufacture biopharmaceutical and IVD equipment for healthcare services.
Dymind
Venture Round in 2016
Dymind specializes in the development, manufacture, sale, and service of medical devices.
inui
Series B in 2015
inui Health is a consumer medical diagnostics company located in Silicon Valley, focused on making medical-grade information accessible to individuals at any time and place. The company has developed a cloud-based diagnostic platform that operates in a mobile environment, allowing consumers to access their health information easily. Their products aim to assist users in detecting health complications early, monitoring their overall health, and sharing pertinent information with healthcare providers for timely interventions. The first product to be launched is the inui In-Home Urine Analysis test system, which offers immediate lab test results for patients and physicians. These innovations empower consumers to manage their health and monitor various conditions, including kidney function and urinary tract infections.
Admera Health
Series A in 2015
Admera Health, LLC is a molecular diagnostics company based in South Plainfield, New Jersey, specializing in personalized medicine and non-invasive cancer testing. The company operates a laboratory dedicated to developing, validating, and delivering proprietary laboratory-developed tests. Among its offerings are PGxOne, a pharmacogenomics test that assesses patient drug responses based on genetic profiles, and DNA sequencing services for analyzing genetic mutations related to cancer. Admera's product pipeline includes the OncoGxOne cancer panel, which identifies genomic variations associated with cancer and treatment options, as well as the FloraCheck microbiome test that evaluates bacterial composition in relation to health. Founded in 2012, Admera Health aims to meet medical needs through innovative diagnostics, utilizing next-generation sequencing and advanced bioinformatics to enhance patient care and outcomes.
MID Labs
Venture Round in 2014
MID Labs was founded by Dr. Carl Wang in 1981 and has been associated with vitreoretinal surgery from its infancy. Not only has MID Labs invented the tools for modern vitrectomy, but as a company, it has been instrumental in revolutionizing the ophthalmic field through its products. MID Labs continues to innovate with the MID Labs branded product line which is supplied to more than 30 countries around the world. These products set the standard for precision, performance, and quality.
AusperBio
AusperBio is a clinical-stage biopharmaceutical company focused on developing innovative treatments for hepatitis B and advancing oligonucleotide therapeutics. Utilizing its proprietary Med-Oligo™ ASO platform, the company aims to enhance targeted delivery technologies to improve treatment outcomes. AusperBio is dedicated to addressing a variety of diseases, including viral infections, genetic disorders, metabolic conditions, and immune diseases, through its small interfering ribonucleic acid (siRNA) drugs. By concentrating on effective treatment strategies and vaccination for chronic hepatitis B, AusperBio seeks to provide patients with improved therapeutic options and protection against this challenging disease.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.